Eli Lilly and Co was incorporated in Indiana in 1901. The Company is engaged in drug manufacturing business founded in Indianapolis, Indiana, in 1876. The Company discovers, develops, manufactures, and sells products in two business segments: human pharmaceutical products and animal health products. Its human pharmaceutical products include: Neuroscience products, Endocrinology products, Oncology products, cardiovascular products and other pharmaceuticals. Neuroscience products include: Cymbalta, Zyprexa, Strattera, Prozac, Symbyax, Amyvid; Endocrinology products: Humalog, Humulin, Byetta, Bydureon, Tradjenta, Jentadueto; Oncology products include: Alimta, Gemzar, Erbitux; Cardiovascular products: Cialis, Effient, ReoPro, Adcirca, Livalo; Other pharmaceutical products include: Vancocin, Ceclor. Animal Health Products segment includes: Rumensin, a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis; Tylan, an antibiotic used to control certain diseases in cattle, swine, and poultry; Micotil, Pulmotil, and Pulmotil AC, antibiotics used to treat respiratory disease in cattle, swine, and poultry, respectively; Paylean and Optaflexx, leanness and performance enhancers for swine and cattle, respectively Posilac, a protein supplement to improve milk productivity in dairy cows; Coban, Monteban, and Maxiban, anticoccidial agents for use in poultry; Apralan, an antibiotic used to control enteric infections in calves and swine; Surmax (sold as Maxus in some countries), a performance enhancer for swine and poultry. The Company competes with a number of multinational pharmaceutical companies, biotechnology companies, and generic pharmaceutical companies. Its operations are regulated extensively by numerous national, state, and local agencies. The FDA extensively regulates all aspects of manufacturing quality for human pharmaceuticals under its current Good Manufacturing Practices (cGMP) regulations.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.